Speciality: Pulmonary Medicine
Description:
A warm welcome to all the medical professionals in this interesting session on Role of IgE inhibitors in Severe allergic Asthma
IgE inhibitors have emerged as a critical treatment option for patients with severe allergic asthma, providing a targeted approach to managing this chronic condition. These inhibitors work by binding to immunoglobulin E (IgE), a key antibody involved in allergic reactions, preventing it from interacting with allergens and triggering asthma symptoms. Omalizumab, the first approved IgE inhibitor, has shown substantial efficacy in reducing asthma exacerbations, improving lung function, and enhancing overall quality of life for patients with severe allergic asthma.
The use of IgE inhibitors is particularly beneficial for patients whose asthma is not well-controlled with standard treatments such as inhaled corticosteroids and long-acting beta-agonists. By specifically targeting IgE, these inhibitors address the underlying allergic component of asthma, leading to a significant reduction in inflammation and hypersensitivity. Clinical studies have demonstrated that IgE inhibitors can decrease the frequency of asthma attacks, reduce the need for emergency medical interventions, and lower the dose of other asthma medications required for control.
Therefore, get an overall knowledge of role of IgE inhibitors in severe allergic asthma
See More Webinars @ Hidoc Webinars
1.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
4.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
5.
Virtual Reality Travel Reduces Cancer Pain.
1.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
2.
Iron Homeostasis Throughout the Female Lifespan
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Exercise Rehabilitation in Hematologic Disease Survivorship
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation